Floatz Rating
CC41/100
Confidence
Indicative
Sponsor
Merus B.V.
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03526835CT.gov A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Esophageal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Petosemtamab (this asset) | Merus B.V. | P1/2 | CC · 41 |
| Tisotumab Vedotin | Seagen Inc. | P2 | BB |
| Fluorouracilum | Merck Sharp & Dohme LLC | P4 | BB |
| Epirubicin | Sutro Biopharma, Inc. | P3 | B |
| Pembrolizumab | Essen Biotech | P3 | B |
| Cetirizine | Ciusss de L'Est de l'Île de Montréal | P3 | B |
| Docetaxel | Laekna Limited | P2 | B |
| Capecitabine | Shenyang Sunshine Pharmaceutical Co., LTD. | P2 | B |
| Cyclophosphamide | Sutro Biopharma, Inc. | P3 | B |
+42 more in the Esophageal Cancer cohort
Other indications for Petosemtamab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P2 | B · 59 |
| Squamous Cell Lung Carcinoma | — | P2 | CCC · 53 |
| Gastroesophageal Junction Adenocarcinoma | — | P1/2 | CC · 47 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Petosemtamab in Esophageal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/petosemtamab-esophageal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →